Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Phase 1/2 Study to Evaluate Safety, Efficacy, and Pharmacokinetics of EU101, an Agonistic Anti-CD137 (4-1BB) Monoclonal Antibody in Patients With Advanced Solid Tumors

NCT04903873 is registered in ClinicalTrials.gov with Eutilex as lead sponsor.

NCT NCT04903873
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04903873 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Phase 1/2 Study to Evaluate Safety, Efficacy, and Pharmacokinetics of EU101, an Agonistic Anti-CD137 (4-1BB) Monoclonal Antibody in Patients With Advanced Solid Tumors
Lead sponsor
Eutilex
Phase
Phase 1/2
Overall status
Unknown status
Start date
May 31, 2021
Completion date
December 31, 2025
Enrollment
110 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

non-small cell lung cancer, prostate cancer, renal cell cancer metastatic, renal cell carcinoma, solid tumor